Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib with nivolumab and/or ipilimumab versus rucaparib alone in relapsed high-grade serous ovarian cancer
ISRCTN10490346Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Rucaparib alone, Rucaparib + nivolumab and Rucaparib + nivolumab + ipilimumab (3 arms). Primary endpoint: Progression-free survival. Started May 2019; status: completed.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN10490346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10490346.